Neurochemical Endpoints to Inform Early-Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting.

Ann Clin Transl Neurol · 2026 · PMC13394087 · PMID 42260718

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The present data indicate that neurochemical endpoints should be analyzed separately for each SCA in studies of mixed ataxia groups due to highly significant differences between different SCA genotypes at similar stages of disease.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.